Skip to search formSkip to main contentSkip to account menu

Cediranib Maleate

Known as: 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 
The maleate salt of an indole ether quinazoline derivative with antineoplastic activities. Competing with adenosine triphosphate, cediranib binds to… 
National Institutes of Health

Related topics

Related topics

10 relations
AZD2171Angiogenesis InhibitionFLT1 protein, humanFLT3 protein, human

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer…
5535 Background: O and C have single agent activity in recurrent platinum-sensitive high-grade serous ovarian cancer (HGSOC). A… 
2014
2014
Cediranib Delays Disease Progression in Advanced Cervical Cancer
Adding the TKI cediranib to chemotherapy improved progression-free survival in patients with metastatic or relapsed cervical… 
2013
2013
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours
PurposeTo investigate any effect of a CYP3A4 inhibitor (ketoconazole) or inducer (rifampicin) on cediranib steady-state… 
2013
2013
Antiangiogenese mit Cediranib im Vergleich zu Placebo
Hintergrund und Fragestellung: In der Erstlinientherapie metastasierter kolorektaler Karzinome (mCRC) sind weiterhin… 
2013
2013
Abstract 1042: Maintenance or switch maintenance therapy with selumetinib or cediranib after chemoradiation prolongs survival in an orthotopic human lung cancer model.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background The outcome of lung cancer is poor and… 
2012
2012
Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.
2011
2011
Dual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranib in advanced solid tumors.
3065 Background: We evaluated the safety of a combination of bevacizumab (B) and a TKI against VEGFR-cediranib (C). METHODS… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)